Burleson & Co’s VistaGen Therapeutics VTGN Stock Holding History

Burleson & Co’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12	Closed	-$1K	–	408
2021 Q1	$1K	Buy	+12	New	+$801	﹤0.01%	355

Other funds holding VTGN

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Burleson & Co's VTGN Position: Q2 2021 in Review

Burleson & Co sold out of VistaGen Therapeutics (VTGN) in Q2 2021, closing a stake of 12 shares — an estimated $1K sold.

Burleson & Co first reported a position in VTGN in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 101 funds tracked by Wall St. Rank hold VTGN as of Q2 2021.

Burleson & Co reported no remaining VistaGen Therapeutics position as of Q2 2021 after selling out during the quarter.
Burleson & Co sold 12 VistaGen Therapeutics shares in Q2 2021, an estimated $1K.
Burleson & Co first reported a position in VistaGen Therapeutics in Q1 2021 and held it in 1 quarter.
Burleson & Co's VistaGen Therapeutics position peaked at $1K in Q1 2021.
101 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2021.

Based on Burleson & Co's 13F filing for Q2 2021, filed 22 Jul 2021.